The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...